Article title: Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2− metastatic breast cancer: a retrospective chart review in community oncology practices in the US
Authors: Jipan Xie, Yanni Hao, Nanxin Li, Peggy L. Lin, Erika Ohashi, Valerie Koo, James E. Signorovitch, Eric Q. Wu & Denise A. Yardley
Journal: Current Medical Research and Opinion
Bibliometrics: Volume 31, Number 6, pages 1095–1103
DOI: https://doi.org/10.1185/03007995.2015.1021906
Since this article was first published, author Denise A. Yardley has updated her declarations. The other authors on this paper have no updates and nothing further to declare.
This has now been updated in the online version of the article. The correct declaration details for D. A. Yardley now read:
‘D.A.Y. reports non-financial support from Celgene pertaining to the work submitted. D.A.Y. reports grants to her institution, Sarah Cannon Research Institute, for studies on which she served as Principal Investigator, outside of the submitted work, from the following companies: Novartis, Janssen, Roche/Genentech, Bristol-Myers Squibb, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Medimmune, Medivation, Pfizer, Sanofi, Tesaro, Eisai, AbbVie, Astellas, Biomarin, Celldex, Clovis, Incyte, Merrimack, Imclone, Luitpold, Macrogenics, and Veridex. D.A.Y. reports that consulting fees were paid to her institution by the following companies for Dr. Yardley’s services: Novartis, Roche/Genentech, Celgene, Lilly, Pfizer, Abraxis, Eisai, Spectrum, bioTheranostics, Celldex and OncoPlex Diagnostics. D.A.Y. reports non-financial support to her institution from Astellas, Sanofi, Lilly, and Celgene.’